期刊文献+

美罗华联合CHOP方案治疗老年弥漫大B细胞性淋巴瘤的临床研究

A Study of Rituximab Combined with ECHOP Regimen for Treatment of the Elderly Patients with Diffuse Large B-Cell Lymphoma
原文传递
导出
摘要 目的观察美罗华(利妥昔单抗,Rituximab)联合COTP方案化疗治疗方案治疗老年弥漫大B细胞性淋巴瘤的临床疗效和毒副反应。方法13例老年弥漫大B细胞淋巴瘤行RCHOP方案:美罗华375mg/m^2,静脉滴注,每1个周期第1天(d1);环磷酰胺750mg/m^2,静脉注射,d1;表阿霉素60mg/m2,静脉注射,d1;长春新碱1.4mg/m^2,静脉注射,d1;强的松100mg,口服,d1-d5每21d为1个周期,重复治疗。全部13例患者完成6个周期化疗后进行疗效评价,随访观察生存情况。结果总有效率(CR+PR)84.6%(11/13),1年PFS率为76.9%(10/13),1年总生存率为92.3%(12/13)。结论美罗华联合CHOP(RCHOP)方案治疗老年弥漫大B细胞淋巴瘤安全、有效。 Objective To evaluate the efficacy and toxicity of combination chemotherapy consisting of Rituximab and CHOP(R-CHOP) in elderly patients with diffuse large B-cell lymphoma. Methods 13 patients with elderly patients with diffuse large B-cell lymphoma treated with the Rituximab and CHOP(R-CHOP) regimen. R-CHOP regimen : Rituximab 375 mg/m^2 was infused on the first day, Cyclophosphamide 750 mg/m^2 IV, Vincristine 1.4 mg/m^2 IV, and Epirubicin 60 mg/m^2 IV were administered on the first day of the chemotherapy course;Prednisone 100 mg was administered orally from the first day to the fifth day;the cycle was repeated every 21 days. All of the patients have received at least 6 chemotherapy cycles. The therapeutic effect was assessed. All patients were followed up. Results Overall response rate were 84. 6%, The 1-year progression free and overall survial rates were 76.9% and 92. 3 %. Conclusion Combination chemotherapy including Rituximab and CHOP(R-CHOP) is effective and safety in treatment for elderly patients with diffuse large B-ceil lymphoma.
出处 《中国临床实用医学》 2010年第3期61-62,共2页 China Clinical Practical Medicine
关键词 弥漫大B细胞性淋巴瘤 美罗华 化疗 Diffuse large B-cell lymphoma Rituximab Chemotherapy
  • 相关文献

参考文献6

二级参考文献26

  • 1Coiffier B, Lepage E. Prognosis of aggressive lymphomas :a study of five prognostic models with patients included in the LNH-84 regimen [J]. Blood, 1989,74(2) :558-564.
  • 2Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20 [J]. Blood, 1994,83(2) :435-445.
  • 3Coiffier B, Haioun C, Ketterer N, et al. Rituximab (antiCD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma., a multicenterphase Ⅱ study [J]. Blood, 1998,92(6) : 1927-1932.
  • 4The Non-Hodgkin's Lymphoma Pathologic Classification Project.National Cancer Institute sponsored study of classification of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage [J]. Cancer, 1982,49(10) : 2112-2135.
  • 5Tedder TF, Engel P. CD20:a regulator of cell-cycle progression of B lymphocytes [J]. Immunol Today, 1994,15(9):450-454.
  • 6Demidem A,(IDEC-C2B8)lymphoma cellCancer BiotherLam T, Alas S, et al. Chimeric anti-CD20 monoclonal antibody sensitizes a B cell line to cell killing by cytotoxic drugs [J].Radiopharm, 1997, 12(3) : 177-186.
  • 7Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma [J]. N Engl J Med, 2002,346(4) :235-242.
  • 8McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond totreatment program [J]. J Clin Oncol, 1998,162833.a four-dose(8):2825-2833.
  • 9Shipp MA, Harrington DP, Klatt MM, et al. Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD [J]. Ann Intern Med,1986, 104(6) : 757-765.
  • 10Elias L,Portlock CS,Rosenberg SA. Combination chemotherapy of diffuse histiocytic lymphoma with cyclophosphamide,adriamycin, vincristine and prednisone (CHOP) [J]. Cancer,1978.42(4) : 1705-1710.

共引文献65

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部